Response To: Correspondence on "Associations of Baseline Use of Biologic or Targeted Synthetic Dmards with Covid-19 Severity in Rheumatoid Arthritis: Results from the Covid-19 Global Rheumatology Alliance Physician Registry" by Sparks Et Al
AuthID
P-017-N4E
P-017-N4E